deltatrials
Completed PHASE3 NCT00334828

ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients With Severe Sepsis

Sponsor: Eisai Inc.

Conditions Severe Sepsis
Interventions Placebo eritoran tetrasodium
Updated 9 times since 2017 Last updated: Jul 21, 2017 Started: Jun 30, 2006 Primary completion: Jan 31, 2011

A PHASE3 clinical study on Severe Sepsis, this trial is completed. The trial is conducted by Eisai Inc. and has accumulated 9 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

9 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Apr 2022 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jan 2021 — Apr 2022 [monthly]

    Completed PHASE3

▶ Show 4 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  2. Sep 2017 — Jun 2018 [monthly]

    Completed PHASE3

  3. Feb 2017 — Sep 2017 [monthly]

    Completed PHASE3

  4. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Jun 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eisai Inc.
Data source: Eisai Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aachen, Germany, Adelaide, Australia, Afula, Israel, Aichi, Japan, Alberton, South Africa, Alcala de Henares Madrid, Spain, Almada, Portugal, Amadora, Portugal, Amiens, France, Amsterdam, Netherlands and 240 more location s